|Hyperion Therapeutics, Inc.|
2000 Sierra Point Parkway
United States - Map
Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The companys products include RAVICTI, which is used as a nitrogen-binding agent for chronic management of adult and pediatric urea cycle disorder (UCD) patients greater than two years of age, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone; and BUPHENYL, an FDA-approved therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.
|Hyperion Therapeutics, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 8. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Donald J. Santel M.S., B.S.E.,
Chief Exec. Officer, Pres and Director
|Mr. Jeffrey S. Farrow ,
Chief Financial Officer and Principal Accounting Officer
|Ms. Ashley C. Gould ,
Chief Legal & Compliance Officer, Sr. VP of Gov. Affairs and Sec.
|Ms. Natalie C. Holles ,
Sr. VP of Corp. & Bus. Devel.
|Mr. Bruce Frederick Scharschmidt M.D.,
Chief Medical Officer and Sr. VP
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|